Property:Outcome specification
This is a property of type Text.
M
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
NI +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
Within > 10 years +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
Grade 3, 4 neutropenia or death within the first 30 days of treatment +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
From the day of randomization until death from any cause +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
Before the start of chemotherapy, every 6 weeks during chemotherapy, then every 3 months for up to 1 year
Measures: EORTC QLQ-C30 (V.3) and Lung module QLQ-LC13 +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
Non-neutropenic toxicities grade 3/4, assessed before each chemotherapy cyle +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Measured with EORTC C-30 Version 3 and EORTC QLQ - H&N35 +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
NA +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Other treatment-associated side effects such as xerostomia, renal impairment, hearing dysfunction, and myelosuppression +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Complete response rate (CR) +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Grade 3 or 4 +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
NA +
Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy +
Toxicity of chemotherapy
Components of Peripheral Neuropathy (according to CTCAE 4.02): sensory, motor, and pain
Data collection points: Start with the first chemotherapy cycle, before each cycle, and then monthly +
Montazeri et al. (2013): Effect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients +
Frequency and severity of nausea and vomiting +
Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial +
Severity, duration and commencement of radiotherapy induced mucositis +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
Efficiancy of supplementation +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
NA +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
NA +